TY - JOUR
T1 - Disparities in Access to Novel Systemic Therapies in Patients With Urinary Tract Cancer
T2 - Propagating Access, Policies and Resources Uniformly
AU - on behalf of the Global Society of Rare Genitourinary Tumors (GSRGT) and the International Bladder Cancer Group (IBCG)
AU - Necchi, Andrea
AU - Joshi, Monika
AU - Bangs, Rick
AU - Makaroff, Lydia
AU - Grivas, Petros
AU - Kamat, Ashish M.
AU - Kassouf, Wassim
AU - Raggi, Daniele
AU - Marandino, Laura
AU - Krupski, Tracey
AU - Flaig, Thomas W.
AU - Spiess, Philippe E.
N1 - Publisher Copyright:
© 2022 Elsevier Inc.
PY - 2023/4
Y1 - 2023/4
N2 - After several decades of therapeutic stagnation, the treatment of patients with urothelial carcinoma has met a revolutionary wave, anticipated by the advent of immune-checkpoint inhibitors (ICI) and followed by newer therapeutic options in the post-ICI setting. These achievements were made in a very short time-frame, thus making the treatment of this disease particularly susceptible to geographical health disparity due to the differences in healthcare systems and approval processes of the regulatory authorities. Furthermore, additional barriers to access innovative care are represented by a limited coverage of clinical trials availability, that is consistent in focusing on selected geographical areas, across trials and clinical settings. Here, we present the current picture of new drug approvals in urothelial carcinoma worldwide, and we also focus our considerations onto the spectrum of ongoing trial inclusion possibilities, trying to understand what are the current gaps in clinical research and routine practice, identifying a way to move forward.
AB - After several decades of therapeutic stagnation, the treatment of patients with urothelial carcinoma has met a revolutionary wave, anticipated by the advent of immune-checkpoint inhibitors (ICI) and followed by newer therapeutic options in the post-ICI setting. These achievements were made in a very short time-frame, thus making the treatment of this disease particularly susceptible to geographical health disparity due to the differences in healthcare systems and approval processes of the regulatory authorities. Furthermore, additional barriers to access innovative care are represented by a limited coverage of clinical trials availability, that is consistent in focusing on selected geographical areas, across trials and clinical settings. Here, we present the current picture of new drug approvals in urothelial carcinoma worldwide, and we also focus our considerations onto the spectrum of ongoing trial inclusion possibilities, trying to understand what are the current gaps in clinical research and routine practice, identifying a way to move forward.
KW - Antibody-drug conjugates
KW - Bladder cancer
KW - Geographical disparity
KW - Immunotherapy
KW - Targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=85143742123&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85143742123&partnerID=8YFLogxK
U2 - 10.1016/j.clgc.2022.10.002
DO - 10.1016/j.clgc.2022.10.002
M3 - Comment/debate
C2 - 36344399
AN - SCOPUS:85143742123
SN - 1558-7673
VL - 21
SP - 301
EP - 308
JO - Clinical Genitourinary Cancer
JF - Clinical Genitourinary Cancer
IS - 2
ER -